Pharmaceutical Executive-11-01-2007

FDAAA aims to restore public trust in drug safety regulation but may curb investment in R&D

Approvable letters delay NDAs, cost pharma plenty, and are at an all-time high. Industry says FDA is gun-shy; the agency says it's business as usual. Who's right?

Top pharma brand experts discuss today's issues: safety, compliance, corporate branding, combatting generics, and more.

With ads on topics ranging from addiction to disease states, this year's Rx Club Award winners connect creativity with emotion

Business intelligence in a time of greater transparency is a whole new ball game. To play it well, be sure to look for surprising insights, expand your list of competitors of interest, and don't let Google be your only guide.

A hospital safety expert says it's now possible to completely eliminate certain adverse events. Pharma can't claim the same yet, but is it time for us to start imagining a time when we can "benchmark perfection"?

Photos from the awards ceremony of the first US Prix Galien, September 25, 2007 in New York City.

In this age of new media, social networking, blogs, and cyber-clutter, it's easy to forget the appeal of the real-of things that you can hold in your hand and engage with physically. But make no mistake, despite all of the high-tech tools available to us, advertising still relies on evoking an emotional response by tickling the human senses.

Will CROs continue to operate in India, or will Novartis' pullout send them farther East?

The impact of high-quality online training tools would be difficult and costly to replicate offline given the dynamic and interactive aspects offered

We have nothing to fear but the fear of change (with apologies to the wise Franklin D. Roosevelt). But we must get over that if we hope to make a real difference.